CombiGene AB (OSTO:COMBI) FCF Margin % : 0.00% (As of Dec. 2024)

View and export this data going back to 2015. Start your Free Trial

What is CombiGene AB FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. CombiGene AB's Free Cash Flow for the three months ended in Dec. 2024 was kr-6.23 Mil. CombiGene AB's Revenue for the three months ended in Dec. 2024 was kr0.00 Mil. Therefore, CombiGene AB's FCF Margin % for the quarter that ended in Dec. 2024 was 0.00%.

As of today, CombiGene AB's current FCF Yield % is -59.78%.

The historical rank and industry rank for CombiGene AB's FCF Margin % or its related term are showing as below:

OSTO:COMBI' s FCF Margin % Range Over the Past 10 Years
Min: -9186.81 Med: -435.36 Max: 26.14
Current: -9186.81

During the past 9 years, the highest FCF Margin % of CombiGene AB was 26.14%. The lowest was -9186.81%. And the median was -435.36%.

OSTO:COMBI's FCF Margin % is ranked worse than
92.39% of 999 companies
in the Biotechnology industry
Industry Median: -120.3 vs OSTO:COMBI: -9186.81

CombiGene AB FCF Margin % Historical Data

The historical data trend for CombiGene AB's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CombiGene AB FCF Margin % Chart

CombiGene AB Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

FCF Margin %

Get a 7-Day Free Trial

26.14

-62.42

-553.14

-9,186.81

CombiGene AB Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
FCF Margin %	Get a 7-Day Free Trial															-1,174.16	-3,047.55	-	-	-

Competitive Comparison of CombiGene AB's FCF Margin %

For the Biotechnology subindustry, CombiGene AB's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CombiGene AB's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CombiGene AB's FCF Margin % distribution charts can be found below:

* The bar in red indicates where CombiGene AB's FCF Margin % falls into.

Save Embed

;

Save Embed

;

CombiGene AB FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

CombiGene AB's FCF Margin for the fiscal year that ended in Dec. 2024 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2024 )	/	Revenue (A: Dec. 2024 )
	=	-29.949	/	0.326
	=	-9,186.81 %

CombiGene AB's FCF Margin for the quarter that ended in Dec. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2024 )	/	Revenue (Q: Dec. 2024 )
	=	-6.231	/	0
	=	%

CombiGene AB FCF Margin % Related Terms

Thank you for viewing the detailed overview of CombiGene AB's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

CombiGene AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CombiGene AB (OSTO:COMBI) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Agavagen 52A, Lidingo, SWE, SE-181 55

Website

https://www.combigene.com

CombiGene AB is a gene therapy explorer based in Sweden. The company is engaged in developing new methods for the treatment of neurological diseases and for epileptic patients who cannot be helped by available medical treatments at present. It develops gene therapies with the ambition to offer patients affected by severe life-changing diseases opportunities for a better life.

CombiGene AB Headlines

No Headlines